News & Events
- 'Turning Science into Business' AI & ML summit: Navigating AI-driven drug discovery
- Transforming Target and Drug Discovery with Visual Biology derived AI Disease Models
- Visual biology AI neural network recognize disease signatures in cellular pathway visualizations
- Leveraging large-scale mRNA biology data to advance disease understanding
- mRNA Is Never Naked: Exploring RBP Target Space & Therapeutic Opportunities
- Technologies developed to study mRNA life cycle
- Exposing hidden targets within the mRNA regulation space
-
Anima Biotech Announces Preclinical Data of Candidate in Idiopathic Pulmonary Fibrosis
When:
Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced today positive preclinical data of its lung fibrosis candidate. This drug operates through a novel mRNA biology mechanism of action, opening new avenues for treating Idiopathic Pulmonary Fibrosis (IPF) patients.
Utilizing its mRNA Lightning™ Platform, Anima has successfully identified a preclinical candidate operating through a novel mRNA biology mechanism of action, effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts. By inhibiting myofibroblasts' deposition of extracellular matrix, this candidate demonstrates substantial potential in mitigating fibrotic diseases. The candidates' oral efficacy in mouse IPF models demonstrates a remarkable safety-to-activity margin and superiority to standard-of-care drugs. It significantly reduces collagen production and fibrotic biomarkers in cells and tissue explants derived from IPF patients. Its clean in vitro ADMET profile further underscores its promise as a breakthrough in fibrotic disease treatment.
"This recent achievement further validates our approach, “said Yochi Slonim, co-founder and CEO of Anima. “Our platform's ability to visualize mRNA biology and decode it with AI technology enables a deeper understanding of disease mechanisms, identification of novel targets, and discovery of drugs that can directly modify the disease phenotype."
Anima’s unique approach is validated by its strategic partnerships with big pharma, including AbbVie, Takeda, and Eli Lilly, and a broad pipeline of discovery programs across Immunology, Oncology, and Neuroscience. Anima’s LightON mRNA | mRNA Biology Masterclass series has become a central forum for over 1,500 industry and academic experts presenting the latest advances in mRNA biology and its applications to drug discovery. -
6th Annual RNA-Targeted Drug Discovery and Development Summit
When:
Where: Boston, MAAnima Biotech will participate in the 6th Annual RNA-Targeted Drug Discovery and Development Summit taking place in Boston, MA from December 12-14, 2024. Our Vice President of Business Development, Gal Gur, Ph.D., will participate on a panel titled, “Overcoming Key Challenges to Improve Drug Design & Discovery for Novel Approaches,” on Wednesday, December 13th at 3:30 PM ET and will also give a presentation titled, “AI in mRNA Biology: Small Molecule Drug & Target Discovery,” on Thursday, December 14th at 12:30 PM ET.
-
BioSpace Webinar | mRNA is Never Naked, Exploring RBP Target Space & Therapeutic Opportunities
When:
Anima presents its third webinar, a part of its exclusive LightON mRNA | mRNA Biology Masterclass series. The mRNA Biology Masterclasses latest webinar, titled, “mRNA is Never Naked, Exploring RBP Target Space & Therapeutic Opportunities,” in partnership with BioSpace will take place on November 14th at 11:00 AM EST.
-
5th Annual Small Molecules Targeting RNA
When:
Anima Biotech will participate in the 20th Anniversary event for Discovery on Target, as part of the 5th Annual Small Molecules Targeting RNA conference taking place in Boston, MA, and virtually. Our co-founder and Chief Scientific Officer, Iris Alroy, will give a remote presentation titled, Discovery of Small Molecules Regulating mRNA and Identification of Novel mRNA Regulatory Target Proteins on September 27th at 8:00 am ET.
-
GEN webinar | Technologies developed to study mRNA life cycle
When:
Join our Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D. as she and other experts delve into innovative technologies that harness mRNA regulation to advance future therapeutics - from splicing and export to localization, degradation, stabilization, and translation.
-
RNA Leaders USA 2023
When:
Where: Boston, MAAnima Biotech will participate in the RNA Leaders USA Congress, as part of the Small Molecules Targeting RNA track of the conference, being held in Boston, MA. Our Senior Director of Corporate Development and Marketing, Clara Assouline, will give a presentation titled, “mRNA Lightning | Discovery of small molecule mRNA drugs and novel mRNA biology targets”, on September 6th at 4:50 pm ET.
-
BIO International Convention 2023
When:
Where: Boston, MAAnima Biotech will be attending this year’s BIO International Convention. Our chief business officer, Kevin Pong, Ph.D., is looking forward to connecting with other industry experts. Additionnaly, he will give a corporate presentation on June. 5th at 3:45 P.M. EDT highlighting our unique approach to the discovery of small molecule mRNA drugs.
-
Locust Walk RNA Innovation Conference
When:
Where: VirtualAnima Biotech has been invited to give a presentation during the Locust Walk RNA innovation event as part of the RNA-Targeting SMOLs track of the Conference held virtually on May 9th. Our chief scientific officer and co-founder, Iris Alroy Ph.D., will give a presentation titled, “Advancing mRNA Lightning™ for the discovery of small molecule mRNA modulators and their mechanisms of action using phenotypic screening and AI driven MOA elucidation” from 1:20 – 1:40 AM ET.
-
Endpoints Webinar | Exposing hidden targets within the mRNA regulation space
When:
Join our Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D. as she and other experts delve into the regulatory mechanisms that oversee mRNA translation and how the latest advancements in mRNA regulation research have identified emerging targets for drug discovery and therapeutic intervention.
-
4th Annual RNA-Targeting Small Molecule Drugs hosted by CHI as part of the 18th Annual Drug Discovery Event
When:
Where: San Diego, CA & VirtualAnima Biotech has been invited to give a presentation during the 18th Annual Drug Discovery Chemistry as part of the RNA-Targeting Small Molecule Drugs track of the Conference held from April 10th to April 13th, 2023 in San Diego, CA and virtually. Our chief scientific officer and co-founder, Iris Alroy Ph.D., will give a presentation titled, “Discovery of Small Molecule mRNA Modulators Using Phenotypic Screening with AI-Driven MoA Elucidation” on Tuesday, April 11, 2023 from 8:10 – 8:40 AM PDT.